Western Horizons Care Center | |
1104 Hwy 12, Hettinger, North Dakota 58639 | |
(701) 567-2401 | |
Name | Western Horizons Care Center |
---|---|
Location | 1104 Hwy 12, Hettinger, North Dakota |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 45 |
Occupancy Rate | 80.67% |
Medicare ID (CCN) | 355042 |
Legal Business Name | Western Horizons Living Centers |
Ownership Type | Non Profit - Corporation |
NPI Number | 1942295480 |
Organization Name | LANTIS ENTERPRISES, INC |
Doing Business As | HILLCREST CARE CENTER |
Address | 1104 Highway 12, Hettinger, ND 58639 |
Phone Number | 701-567-2401 |
News Archive
An advisory panel for the US Food and Drugs Administration voted 9-6 that the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight. Signals of possible liver damage and of breast and bladder cancer worried the experts.
In just the past few years, researchers have found a way to use a naturally occurring bacterial system known as CRISPR/Cas9 to inactivate or correct specific genes in any organism. CRISPR/Cas9 gene editing activity runs continuously, though, leading to risk of additional editing at unwanted sites. Now, researchers at University of California, San Diego School of Medicine, Ludwig Cancer Research and Isis Pharmaceuticals demonstrate a commercially feasible way to use RNA to turn the CRISPR-Cas9 system on and off as desired - permanently editing a gene, but only temporarily activating CRISPR-Cas9.
GE Capital, Healthcare Financial Services announced today that it served as agent and sole lender to Mitralign, Inc. for a $5 million senior secured credit facility. Mitralign will use the credit facility for working capital as the company advances development of its mitral valve repair device.
Dr. Robert C. Bray of the University of Calgary was recently selected as the winner of the American Orthopaedic Society for Sports Medicine's (AOSSM) $250,000 Ligament and Tendon Repair and Regeneration Grant for his project, "Biological Augmentation of Ligament and Tendon Healing: Role of Neuropeptides."
› Verified 4 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
An advisory panel for the US Food and Drugs Administration voted 9-6 that the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight. Signals of possible liver damage and of breast and bladder cancer worried the experts.
In just the past few years, researchers have found a way to use a naturally occurring bacterial system known as CRISPR/Cas9 to inactivate or correct specific genes in any organism. CRISPR/Cas9 gene editing activity runs continuously, though, leading to risk of additional editing at unwanted sites. Now, researchers at University of California, San Diego School of Medicine, Ludwig Cancer Research and Isis Pharmaceuticals demonstrate a commercially feasible way to use RNA to turn the CRISPR-Cas9 system on and off as desired - permanently editing a gene, but only temporarily activating CRISPR-Cas9.
GE Capital, Healthcare Financial Services announced today that it served as agent and sole lender to Mitralign, Inc. for a $5 million senior secured credit facility. Mitralign will use the credit facility for working capital as the company advances development of its mitral valve repair device.
Dr. Robert C. Bray of the University of Calgary was recently selected as the winner of the American Orthopaedic Society for Sports Medicine's (AOSSM) $250,000 Ligament and Tendon Repair and Regeneration Grant for his project, "Biological Augmentation of Ligament and Tendon Healing: Role of Neuropeptides."
› Verified 4 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 2 |
Total Amount of Fines in Dollars | $11138 |
Number of Payment Denials | 0 |
Total Number of Penalties | 2 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 20 | 14.46 |
Percentage of long-stay residents who lose too much weight | 3.85 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 37.25 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 3.07 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.24 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 3.36 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 6.38 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 18.8 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 66.67 | 83.88 |